Ep. 172 - AACR Insights
BioCentury This Week
00:00
The Merck and Moderna Neo Antigen Cancer Vaccine Combo
The latest melanoma data for the Merck and Moderna Neo antigen vaccine combo we did see top line data back in December that data was very well received by investors. But it garnered a much more pessimistic market response. And so there was a lot of questions about the balance of molecularly defined subgroups across the katru to only control arm versus the combination arm with the neo antigen cancer vaccine.
Transcript
Play full episode
